1. Home
  2. KYMR vs FA Comparison

KYMR vs FA Comparison

Compare KYMR & FA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KYMR
  • FA
  • Stock Information
  • Founded
  • KYMR 2015
  • FA 2003
  • Country
  • KYMR United States
  • FA United States
  • Employees
  • KYMR N/A
  • FA N/A
  • Industry
  • KYMR Medicinal Chemicals and Botanical Products
  • FA Business Services
  • Sector
  • KYMR Health Care
  • FA Consumer Discretionary
  • Exchange
  • KYMR Nasdaq
  • FA Nasdaq
  • Market Cap
  • KYMR 3.0B
  • FA 3.3B
  • IPO Year
  • KYMR 2020
  • FA 2021
  • Fundamental
  • Price
  • KYMR $42.30
  • FA $19.33
  • Analyst Decision
  • KYMR Buy
  • FA Buy
  • Analyst Count
  • KYMR 16
  • FA 8
  • Target Price
  • KYMR $54.00
  • FA $20.80
  • AVG Volume (30 Days)
  • KYMR 456.9K
  • FA 951.0K
  • Earning Date
  • KYMR 10-31-2024
  • FA 11-12-2024
  • Dividend Yield
  • KYMR N/A
  • FA N/A
  • EPS Growth
  • KYMR N/A
  • FA N/A
  • EPS
  • KYMR N/A
  • FA 0.03
  • Revenue
  • KYMR $87,563,000.00
  • FA $755,643,000.00
  • Revenue This Year
  • KYMR N/A
  • FA $17.68
  • Revenue Next Year
  • KYMR $33.16
  • FA $81.35
  • P/E Ratio
  • KYMR N/A
  • FA $566.99
  • Revenue Growth
  • KYMR 86.92
  • FA N/A
  • 52 Week Low
  • KYMR $22.35
  • FA $14.01
  • 52 Week High
  • KYMR $53.27
  • FA $20.79
  • Technical
  • Relative Strength Index (RSI)
  • KYMR 41.34
  • FA 51.78
  • Support Level
  • KYMR $40.95
  • FA $19.55
  • Resistance Level
  • KYMR $44.17
  • FA $20.37
  • Average True Range (ATR)
  • KYMR 2.32
  • FA 0.47
  • MACD
  • KYMR -0.33
  • FA -0.05
  • Stochastic Oscillator
  • KYMR 16.07
  • FA 27.87

About KYMR Kymera Therapeutics Inc.

Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.

About FA First Advantage Corporation

First Advantage Corp is a provider of employment background screening and verification solutions. The company delivers services and insights that help its customers manage risk and hire talent. The Company has two reportable segments, Americas and International. The Americas segment provides technology solutions for screening, verifications, safety, and compliance in the United States, Canada, and Latin America markets. and the International segment provides technology solutions for screening, verifications, safety, and compliance outside of the Americas. The company derives its maximum revenue from America.

Share on Social Networks: